Total Payments
$123,433
2024 Payments
$58,250
Companies
22
Transactions
130
Medicare Patients
16,075
Medicare Billing
$983,301
Payment Breakdown by Category
Research$110,969 (89.9%)
Travel$9,281 (7.5%)
Food & Beverage$3,108 (2.5%)
Education$76.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $110,969 | 15 | 89.9% |
| Travel and Lodging | $9,281 | 44 | 7.5% |
| Food and Beverage | $3,108 | 69 | 2.5% |
| Education | $76.00 | 2 | 0.1% |
Payments by Type
Research
$110,969
15 transactions
General
$12,464
115 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $115,721 | 65 | $0 (2024) |
| F. Hoffmann-La Roche AG | $1,964 | 3 | $0 (2017) |
| Janssen Research & Development, LLC | $1,744 | 7 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,443 | 11 | $0 (2023) |
| Novartis Pharma AG | $1,257 | 6 | $0 (2018) |
| Eli Lilly Export S.A. Puerto Rico Branch | $790.46 | 1 | $0 (2020) |
| Amgen Inc. | $78.28 | 5 | $0 (2019) |
| Genentech, Inc. | $76.00 | 2 | $0 (2018) |
| Lilly USA, LLC | $74.56 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $49.30 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,250 | 48 | Eli Lilly and Company ($58,250) |
| 2023 | $2,175 | 12 | Merck Sharp & Dohme LLC ($1,428) |
| 2020 | $2,956 | 7 | Eli Lilly and Company ($2,151) |
| 2019 | $20,541 | 9 | Eli Lilly and Company ($20,451) |
| 2018 | $37,370 | 39 | Eli Lilly and Company ($34,121) |
| 2017 | $2,140 | 15 | F. Hoffmann-La Roche AG ($1,964) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $27,766.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $24,815.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,752.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 08/21/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $162.16 | General |
| 08/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $293.02 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $175.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $118.73 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.79 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.01 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $33.17 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $32.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $17.50 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $15.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $8.28 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $4.14 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $3.31 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $53,097 | 5 |
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $27,766 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $24,815 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $2,287 | 2 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | Eli Lilly and Company | $827.96 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | Eli Lilly and Company | $827.96 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly Export S.A. Puerto Rico Branch | $790.46 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $258.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $212.35 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $87.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 4,415 | 4,846 | $672,190 | $275,875 |
| 2022 | 19 | 4,012 | 4,369 | $597,696 | $255,986 |
| 2021 | 18 | 3,835 | 4,266 | $557,016 | $244,990 |
| 2020 | 22 | 3,813 | 4,391 | $514,146 | $206,450 |
Total Patients
16,075
Total Services
17,872
Medicare Billing
$983,301
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 631 | 631 | $147,244 | $77,468 | 52.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 379 | 396 | $102,334 | $48,640 | 47.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 1,027 | 1,027 | $166,231 | $36,401 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 438 | 499 | $95,638 | $34,909 | 36.5% |
| 77067 | Screening mammography | Office | 2023 | 221 | 221 | $38,675 | $18,798 | 48.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 166 | 167 | $19,205 | $12,632 | 65.8% |
| 90671 | Pneumococcal conjugate vaccine, 15 valent (pcv15), for intramuscular use | Office | 2023 | 51 | 51 | $25,613 | $12,305 | 48.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 123 | 141 | $18,355 | $8,230 | 44.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 662 | 933 | $14,928 | $7,830 | 52.5% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 221 | 221 | $9,525 | $4,895 | 51.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 168 | 169 | $6,084 | $4,833 | 79.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 12 | 12 | $4,137 | $1,885 | 45.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 35 | 39 | $2,938 | $1,847 | 62.9% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 58 | 58 | $1,931 | $1,659 | 85.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 19 | 26 | $1,801 | $932.10 | 51.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 21 | $1,626 | $637.95 | 39.2% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 95 | 99 | $8,051 | $560.34 | 7.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 11 | 12 | $1,992 | $482.60 | 24.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 28 | 29 | $2,472 | $302.68 | 12.2% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 14 | 17 | $1,305 | $254.11 | 19.5% |
| 73502 | X-ray of hip, 2-3 views | Office | 2023 | 11 | 11 | $1,015 | $184.21 | 18.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 13 | 14 | $763.00 | $154.30 | 20.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 52 | $325.00 | $33.22 | 10.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 615 | 615 | $132,872 | $76,981 | 57.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 475 | 511 | $124,996 | $59,938 | 48.0% |
About Dr. Michael Cox, MD
Dr. Michael Cox, MD is a Internal Medicine healthcare provider based in Topeka, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275593451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Cox, MD has received a total of $123,433 in payments from pharmaceutical and medical device companies, with $58,250 received in 2024. These payments were reported across 130 transactions from 22 companies. The most common payment nature is "" ($110,969).
As a Medicare-enrolled provider, Cox has provided services to 16,075 Medicare beneficiaries, totaling 17,872 services with total Medicare billing of $983,301. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Topeka, KS
- Active Since 03/23/2006
- Last Updated 02/06/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1275593451
Products in Payments
- Non-Covered Product (Drug) $2,040
- LCZ696B (Drug) $1,257
- TRULICITY (Drug) $74.56
- Prolia (Biological) $65.82
- CHANTIX (Drug) $47.35
- ELIQUIS (Drug) $40.38
- Trulance (Drug) $28.12
- RAYOS (Drug) $17.80
- Trintellix (Drug) $15.85
- BELSOMRA (Drug) $15.12
- SYNTHROID (Drug) $14.79
- TRELEGY ELLIPTA (Drug) $13.01
- VRAYLAR (Drug) $12.91
- Aimovig (Biological) $12.46
- SHINGRIX (Biological) $12.46
- BREO (Drug) $12.30
- Movantik (Drug) $12.21
- FARXIGA (Drug) $12.00
- ADVAIR (Drug) $11.53
- Victoza (Drug) $11.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Topeka
Scott Teeter, Md, MD
Internal Medicine — Payments: $25,736
Internal Medicine $25,736
Katherine Willingham, Md, MD
Internal Medicine — Payments: $21,137
Internal Medicine $21,137
Dr. John Rockefeller, M.d, M.D
Internal Medicine — Payments: $3,519
Internal Medicine $3,519
Dr. Hemant Boolani, M.d, M.D
Internal Medicine — Payments: $2,982
Internal Medicine $2,982
Jamal Akhtar, M.d, M.D
Internal Medicine — Payments: $2,075
Internal Medicine $2,075
Dr. Jed Mckee, Md, MD
Internal Medicine — Payments: $1,556
Internal Medicine $1,556